WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

A CLINICAL STUDY TO EVALUATE EFFICACY OF “HINGVADI CHURNA” IN THE MANAGEMENT OF KASHTARTAVA WITH SPECIAL REFRENCE TO PRIMARY DYSMENORRHEA

Dr. Renu*, Dr. B. Pushpalatha and Dr. K. Bharathi

ABSTRACT

Dysmenorrhea is the most common gynecological problem faced by women during their adolescence which causes significant discomfort and anxiety for the women as well as family. Dysmenorrhoea is defined as painful menstruation so as to incapacitate day to day activities. Primary dysmenorrhea is extremely common, especially among adolescents. In modern medicine dysmenorrhea is treated by oral contraceptive pills, non-steroidal anti-inflammatory drugs, antispasmodic, analgesics etc. Long term use of these causes side effects. So to minimize these complications, an attempt is made to find solution of this problem. There is a great scope of research with long lasting effect, to treat the entire feature complex with single regimen and find out the treatment for the underlying pathology from Ayurveda for the management of Kashtartava. In Ayurveda Kashtartava, term which is being used for the condition where in a women may suffer with pain during menstruation. Pain is the main feature of Kashtartava, so it has strong relation with Vata Dosha. Agnivikara induces vitiation of Apana Vata. Therefore the drug is selected to correct both Agnivikara and vitiated Vata and Hingvadi Churna has a direct reference in Chakradutta 26/72 for Kashtartava. Keeping this point in view, the present clinical trial, A Clinical Study to Evaluate Efficacy of “Hingvadi Churna” In the Management of Kashtartava with Special Reference to Primary Dysmenorrhea was taken. The medicine started from 7 days before due date of menstrual cycle to next 02 consecutive menstrual cycles or 60 days. Results were assessed on the basis of improvement in the subjective parameters. The study reveals that patients of Kashtartava after treatment showed significant improvement in chief complaints, from the above trial it is clear that Hingvadi Churna can be used as a safe and effective therapeutic agent in the management of Kashtartava.

Keywords: Dysmenorrhea, Vatadosha, Agnivikara.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More